2667 results about "Pharmaceutical formulation" patented technology

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

The invention relates to the technical field of exosome loaded drugs, and provides a preparation method and application of exosome vesicles capable of efficiently loading drugs, and the preparation method comprises the following steps: exosome preparation: preparing an exosome sample with enough granularity and purity; pretreatment of exosomes: performing precipitation treatment and collecting the exosomes to prepare exosome precipitates; carrying out loaded medicine pretreatment: treating loaded medicine or a medicine preparation by using a lipid reagent; target drug loading: rapidly treating the exosome precipitate by using a drug lipid component, and then treating by using a buffer system to obtain the exosome load of the drug; and free lipid and drug removal: reducing free lipid and drug residues by re-enriching the exosomes. The problems of high concentration, high purity and low cost in industrial production of the exosome are solved, meanwhile, an efficient and convenient technical method is provided for taking the exosome loaded medicine as a delivery system, and the method can be suitable for the fields of health medical treatment, medical beauty cosmetics and biological medicine products.

The present disclosure includes ionizable lipids suitable for lipid nanoparticle compositions and pharmaceutical formulations thereof. The lipids have general formula (I).

Disclosed is a pharmaceutical formulation including a monoclonal OX40 antibody, a buffer, a stabilizer, and a surfactant, which can maintain the stability under various scenarios, such as manufacturing, packaging, sub-packaging, shipping, administration, and / or storage. Also disclosed are the use of the pharmaceutical formulation in the preparation of a drug for treating OX40-associated diseases, in particular, inflammatory and / or autoimmune diseases, and a method for preparing the pharmaceutical formulation.

The invention discloses a brain-targeted active oxygen responsive hydrogen sulfide donor liposome, a preparation method and an application, and belongs to the technical field of pharmaceutical preparations, the structure of the brain-targeted active oxygen responsive hydrogen sulfide donor liposome comprises a lipid material and a hydrogen sulfide donor encapsulated in the lipid material, the lipid material comprises phospholipid, cholesterol, active oxygen sensitive lipid and brain-targeted lipid, and the lipid material comprises phospholipid, cholesterol, active oxygen sensitive lipid and brain-targeted lipid. The active oxygen sensitive lipid comprises a phospholipid lipophilic part, a polyethylene glycol hydrophilic part and an active oxygen sensitive bond, and the brain-targeted lipid comprises a phospholipid lipophilic part, a polyethylene glycol hydrophilic part and brain-targeted peptide. The hydrogen sulfide donor lipidosome can penetrate through a blood brain barrier, target neuronal cells, respond to an active oxygen environment of a focus part and sensitively release a hydrogen sulfide donor, so that hydrogen sulfide is distributed in the focus neuronal cells, active oxygen and active nitrogen substances are effectively removed, oxidation and nitration stress are inhibited, and damage and death of the neuronal cells are reduced; the growth and functional recovery of neuronal cells are promoted, and the application prospect in the aspect of treating central nervous system injury diseases is good.

The invention relates to a curcumin-loaded MMP response type melittin nano-pellicle vesicle as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: firstly, preparing curcumin entrapped lipidosome; then carrying out culture amplification on engineering bacteria carrying melittin recombinant plasmids, extracting cell membranes after removing cell walls, and carrying out ultrasonic treatment and membrane extrusion to obtain melittin cell membrane nano-vesicles; fusing the curcumin lipidosome and the cell membrane nano-vesicles in an ultrasonic extrusion mode to obtain fused vesicles; and finally, carrying out surface calcium phosphate mineralization treatment on the fused vesicles to obtain the curcumin-loaded MMP response type melittin nano pellicle vesicles. The nano mycofilm vesicle prepared by the invention can be used for preparing antitumor drugs, and the biocompatibility and in-vivo stability of nanoparticles are improved by introducing a calcium phosphate coating; through combined delivery of melittin and curcumin, the anti-tumor effect is enhanced, so that the growth and proliferation of tumor cells are inhibited.

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

The invention relates to the technical field of medicine formulas, in particular to a fluralamide moxidectin composite drop and a preparation process thereof. The invention relates to a fluralan-moxidectin emulsion which is prepared from the following raw materials in percentage by mass: 26 to 30 percent of fluralan, 1.1 to 1.7 percent of moxidectin, 32 to 36 percent of solvent, 0.1 to 0.3 percent of butylated hydroxytoluene, 10 to 16 percent of polymer carrier and the balance of tetrahydrofuran polyethylene glycol ether. The coexisting drug is stabilized through the core-shell structure polymer carrier, phase separation is prevented, a neutral environment is maintained, long-acting stability is ensured, the transdermal absorption rate is optimized, skin irritation is reduced, and the synergistic drug effect is improved. Meanwhile, the slow release period of the medicine is prolonged, the metabolic interference and accumulated toxicity are reduced, and the dissolution efficiency and the skin mildness are both considered.

The invention discloses an anti-tumor drug tablet stability prediction method based on multi-source data fusion, and particularly relates to the field of pharmaceutical preparation stability prediction, and the method comprises the following steps: S1, data acquisition; s2, extracting multi-dimensional characteristic parameters; s3, constructing a stability prediction reference model; s4, calculating a real-time attenuation index; s5, determining a deviation threshold range; s6, analyzing a stability deviation index; s7, dynamically updating a prediction result; according to the method, accurate prediction of content attenuation, related substance growth and disintegration time limit change indexes is realized through integration of multi-source data, construction of a stability prediction reference model, simple trend analysis not limited to a single factor, key influence factor marking, critical threshold setting and theoretical attenuation curve fitting; the accuracy and timeliness of stability prediction of antitumor drug tablets are effectively improved, and a scientific basis is provided for drug validity period evaluation and quality risk management and control.

The invention belongs to the technical field of microorganisms, and discloses a high-temperature-resistant vibrio alginolyticus bacteriophage and a composition and application thereof, the high-temperature-resistant vibrio alginolyticus bacteriophage is named as vibrio alginolyticus bacteriophage PJ644 and is preserved in China General Microbiological Culture Collection Center on August 16, 2024, the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.9624. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No. The bacteriophage has excellent high temperature resistance, and the bacteriophage and the bacteriophage composition not only can effectively prevent and treat various vibrio infections, but also can be used as active ingredients for preparing bacteriophage pharmaceutical preparations, aquatic feed additives, water disinfectants and aquatic product preservatives, and are used for effectively preventing and treating diseases caused by vibrio infections in aquaculture farms. The use is safe, and the problems of antibiotic residues and pathogen drug resistance caused by use of antibiotics are effectively avoided.

The invention discloses a preparation method of eye drops for treating glaucoma, cataract and vitreous opacification. The eye drops comprise the following components: berberine, N-acetyl carnosine and lycium barbarum polysaccharide. The specific formula comprises the following components: 0.1%-0.5% of berberine, 1%-3% of N-acetyl carnosine and 0.5%-2% of lycium barbarum polysaccharide. The invention belongs to the technical field of ophthalmic pharmaceutical preparations, and solves the problems that in the prior art, glaucoma, cataract and vitreous opacity generally need to be separately taken, the research on compound preparations is less, and the components possibly interact with one another.

The invention discloses a high-utilization-rate ginseng active ingredient medicinal preparation and a preparation method thereof, and relates to the technical field of medicines. The high-utilization-rate ginseng active ingredient pharmaceutical preparation is prepared from chitosan coated drug-loaded porous silicon dioxide composite nanoparticles and a drug-loaded MIL-101 metal organic framework matrix material, chitosan-coated drug-loading porous silicon dioxide composite nanoparticles are loaded on the surface of a drug-loading MIL-101 metal organic framework base material, and sodium alginate and a chitosan gel material are subjected to cross-linking connection, so that independent coating is formed, the framework base material and the composite nanoparticles are connected into a whole, the encapsulation performance and the drug loading capacity are improved, and the drug-loading capacity of the drug-loading MIL-101 metal organic framework composite nanoparticles is improved. Furthermore, the loading and the loading stability of the ginsenoside are improved, the adverse effects of gastric juice and gastrointestinal peristalsis on the activity of the ginsenoside are effectively reduced, the release and the absorption of the ginsenoside in intestinal tracts are remarkably enhanced, and the bioavailability is relatively high.

The invention relates to a CD19 antibody pharmaceutical preparation. Specifically, the invention relates to the pharmaceutical preparation of the irnerizumab, and the pharmaceutical preparation comprises the irnerizumab, a buffer solution, a stabilizer and a surfactant. The pharmaceutical preparation can prevent aggregation, degradation, oxidation or denaturation and the like of the irnerizumab, so that the biological activity of the effective components of the irnerizumab is maintained, and the pharmaceutical preparation is suitable for clinical use.

The invention discloses a low-temperature vacuum microwave freeze-dried sinomenine hydrochloride preparation and a preparation method thereof in the technical field of pharmaceutical preparations, and solves the problems of long drying time, high energy consumption and poor product stability in the traditional freeze-drying technology. A vacuum microwave collaborative freeze-drying technology is adopted, microwave internal heating is achieved through a 2.45 GHz magnetron microwave generator and a rectangular waveguide tube under the conditions that the vacuum degree is 20-30 Pa and the plate layer temperature ranges from-40 DEG C to-35 DEG C, the microwave power density in the primary drying stage ranges from 0.3 W / g to 0.5 W / g, the microwave power density in the secondary drying stage ranges from 0.1 W / g to 0.3 W / g, and collaborative control over the microwave power, the vacuum degree, the temperature and the time is achieved in cooperation with a quaternary coupling precise control system. The preparation contains 50 mg of sinomenine hydrochloride, 100 mg of mannitol and 10 mg of sodium carboxymethyl cellulose grafted modified polyvinylpyrrolidone, the residual moisture is controlled to be 0.4-0.6%, the activity retention rate is 94-96%, and the drying time is shortened to 12-16 hours.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cyclophosphamide ternary nano-micelle and a preparation method thereof.The cyclophosphamide ternary nano-micelle prepared through the method can be used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like. Reasonable preparation steps and a preparation formula are adopted, the use of an organic reagent is reduced, the irritation of cyclophosphamide is reduced and the stability of the micelle is improved by adjusting a freeze-drying technology, and the cyclophosphamide micelle adopts amphiphilic macromolecules as a carrier material, so that the drug loading capacity and the stability of the micelle are obviously improved, and the bioavailability of the micelle is improved. The ternary nano-micelle system has the advantages that the solubility of cyclophosphamide is improved, the in-vivo bioavailability is increased, the preparation method is simple, the micelle performance is stable, and large-scale industrial production is facilitated.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human lymphocyte activation gene-3 (LAG-3). In certain embodiments, the formulations contain, in addition to an anti-LAG-3 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.

The invention provides a novel crystal form and a novel crystal form APTI-I. The novel crystal form and the novel crystal form APTI-I are radiated by Cu-K alpha, and an X-ray powder diffraction pattern represented by a 2 theta angle has characteristic peaks at 5.0 degrees + / -0.2 degrees, 6.3 degrees + / -0.2 degrees, 7.8 degrees + / -0.2 degrees, 12.2 degrees + / -0.2 degrees and 20.0 degrees + / -0.2 degrees. The crystal form is easy to prepare, high in purity, good in stability, good in solubility in buffer solutions and deionized water solvents with different pH values, and suitable for industrial large-scale production and preparation of pharmaceutical preparations.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a melogabalin besylate tablet containing a stabilizer and a preparation method of the melogabalin besylate tablet. The melogaba besylate tablet containing the stabilizer comprises a coating and a tablet core, wherein the tablet core comprises the following components: melogaba besylate, the stabilizer, a disintegrating agent, a lubricating agent and the balance of a filling agent; and the coating is prepared from the following materials: an Intai W100 film coating premixing agent and acrylic resin IV. The filling agent comprises xylitol, pregelatinized starch and maltodextrin in a mass ratio of (3-4): 3: (1-2). The stabilizer is vitamin E succinic acid polyethylene glycol ester. The coating is prepared from the following materials: an Intai W100 film coating premixing agent and acrylic resin IV in a mass ratio of (1-1): (1-2). According to the melogabalin besylate tablet prepared by the invention, the stability and the dissolution performance can be synchronously improved.

The invention relates to an application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and medicinal preparations. The invention provides application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV (human papillomavirus) infection. The dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. According to the scheme, the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV is reported for the first time, and an in-vitro cell experiment is carried out through azelnidipine in the dihydropyridine compound; furthermore, the inhibition effect on the HPV virus is verified through mouse intradermal vaccination virus model drug delivery and mouse vaginal vaccination virus model drug delivery.

The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

The present application provides compositions comprising aflibercept and variants thereof wherein the variants are truncated variants of a VEGF binding moiety of aflibercept, and wherein the content of the truncated variants is less than or equal to about 20%, calculated by mass percent. The invention further provides a pharmaceutical preparation containing the composition and a preparation method of the pharmaceutical preparation. In addition, the invention also provides a detection method of the variant and application of the variant in quality inspection or quality control of an aflibercept-containing product.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

The invention belongs to the field of medicines, and relates to a heterocyclic compound as shown in formula (I), which can be used as a voltage-gated sodium channel inhibitor, especially has an excellent inhibition effect on Nav1.8, has excellent selectivity and pharmacokinetic properties, and can be applied to prevention, alleviation and / or treatment of voltage-gated sodium channel related diseases.